Backlash grows against anti-flu drug's clinical efficacy and cost

Senior influenza experts have joined a growing backlash against the anti-flu drug Relenza which they fear could have potentially serious financial effects on the NHS and they claim is of unproven clinical effectiveness.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here